Viopas Venture Consulting opens office in the Innovation and Start-up Center Biotechnology (IZB)
July 25, 2023
The consultancy supports start-ups from the healthcare industry in Germany and Switzerland.
Tom Loeser, Partner of VVC and CEO of Viopas Venture Consulting (Germany) GmbH
Martinsried near Munich, July 25, 2023 – The Innovation and Start-up Center for Biotechnology (IZB), one of the leading biotechnology centers in Europe, and home to almost 50 biotech start-ups, today announced that the consulting firm, Viopas Venture Consulting (VVC) has moved into the IZB. Viopas Venture Consulting offers consulting services to companies in the life sciences, biotech, medtech and pharma sectors and assists them with business and financial planning, partnering and licensing, M&A, as well as technical and clinical pharmaceutical product development. By moving into the IZB VVC expands its business activities to Munich, Germany’s largest and most dynamic center for life sciences.
“Being successful entrepreneurs with our own experience in the life sciences sector, we see significant consulting needs of growing start-ups in all business areas – from product development and business strategy to financing and partnerships. We are looking forward to supporting the life science companies located at the IZB with our expertise and international contacts,” said Tom Loeser, Partner of VVC and CEO of Viopas Venture Consulting (Germany) GmbH.
“We would like to welcome Viopas Venture Consulting to IZB. VVC already supports some of our start-ups with their expertise, and we are looking forward to having them on site, so that other growth-stage companies can benefit from their guidance as well,” added Dr Peter Hanns Zobel, Managing Director IZB.
The team at VVC brings together expertise in oncology/immunology, ophthalmology, rare diseases, neurology and neuromuscular diseases, as well as CMC/drug development, and finance. Additionally, Viopas Venture Consulting offers counsel to investors interested in the healthcare sector, including family offices, high-net worth individuals, and institutional investors. The company is headquartered near Zurich (Switzerland) with a second office in Basel (Switzerland), and a newly opened office at the IZB near Munich.
For further information, please see www.viopasventure.ch
Press contact Viopas Venture Consulting
Viopas Venture Consulting
Partner VVC and Managing Director, Viopas Venture Consulting (Germany) GmbH
Tel.: 0173/56 52 697
About the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich
The Fördergesellschaft IZB mbH, founded in 1995, operates the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan and has developed into a leading biotechnology center. More than 50 biotech companies with over 700 employees are currently based on 26,000 m2. Here, work is being done on developing drugs for the most serious diseases, such as cancer, Alzheimer’s and various autoimmune diseases. A key criterion for the success of the IZBs is the physical proximity to cutting-edge research on the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt chemistry college, the two kindergartens Bio Kids and Bio Kids2 as well as the two restaurants SEVEN AND MORE and THE BOWL Food Lounge are also location factors that are highly valued by the founders of the company. Successful companies that emerged from the IZB include Corimmun (today Janssen-Cilag), Crelux (today WuXi AppTec), Exosome Diagnostics (today Bio-Techne), ibidi, Immunic Therapeutics, Medigene, Micromet (today AMGEN), MorphoSys, Octopharma or Rigontec (today MSD) as well as SIRION Biotech (today Perkin Elmer). More information at www.izb-online.de
Susanne Simon, Head of Press and Public Relations
Innovation and Start-up Center for Biotechnology (IZB)
Am Klopferspitz 19